User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

8824

Interactions with Platform & by Email *

INTERACTIONS

1235

Unique # Participated *

PARTICIPANTS

265

Responses Validated *

VALIDATIONS

50

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   Current Scenario and Outlook.....II-1
Asians Lead in Liver Cancer Prevalence and Incidence.....II-1
1$100
   Table 1: Incidence and Mortality of Liver Cancer in Select Countries: 2007 (includes corresponding Graph/Chart).....II-2
Disparity in Epidemiology and Etiology Of Liver Cancer.....II-2
1$350
   Liver Cancer Incidence Rising in the US.....II-3
HCC Incidence Declines in Japan.....II-3
1$100
   Conventional Therapies Plagued with Lower Penetration.....II-4
Therapies and Eligible Patient Population.....II-4
1$100
   Major Target Population Exists for Targeted Therapies.....II-5
Nexavar – The Only Approved Targeted Therapy in Liver Cancer.....II-5
1$100
   Table 2: Global Nexavar Sales (2007-2015) (in US$ Million) (includes corresponding Graph/Chart).....II-6
Japanese Approval for Nexavar® in 2009.....II-6
Nexavar Proves Efficacy in Asian Patients.....II-6
1$350
   Nexavar Ongoing Clinical Trials.....II-7
Nexavar Being Evaluated As Adjuvant Therapy.....II-7
Development of Nexavar Plus Tarceva Therapy Underway.....II-7
Liver Cancer Treatment to Boost Nexavar’s Revenues.....II-7
1$100
   ThermoDox Likely to Enter Market in 2011.....II-8
Table 3: Worldwide ThermoDox Sales: 2011-2015 (includes corresponding Graph/Chart).....II-8
1$350
   Liver Cancer Therapy – Attracting Increasing Research Efforts.....II-9
Combination Drugs to Make an Impact.....II-9
1$100
   Pipeline Drugs in Liver Cancer Treatment - A Snapshot.....II-10
Select Pipeline Drugs in Phase III Clinical Trials for Liver Cancer Treatment.....II-10
Select Pipeline Drugs in Phase II Clinical Trials for Liver Cancer Treatment.....II-10
1$100
   Select Pipeline Drugs in Other Clinical Trial Stages for Liver Cancer
  Treatment.....II-11
1$100
   Overview of Select Drugs In Pipeline.....II-12
Sutent® (Pfizer).....II-12
ThermoDox + RFA (Celsion Corp.).....II-12
Sorafenib + TACE (Bayer).....II-12
1$100
   Sorafenib + Tegafur/Uracil.....II-13
Muparfostat (Formerly PI-88) (Progen Pharmaceuticals/Global TransBiotech).....II-13
Avastin + Tarceva (Roche/Genentech).....II-13
1$100
   NX-1207 (Nymox Pharmaceutical Corp.).....II-14
ALN-VSP (Alnylam Pharmaceuticals, Inc.).....II-14
AV-951 (Aveo Pharmaceuticals).....II-14
1$100
   JX-594 (Jennerex).....II-15
Afinitor/RAD001 (Novartis).....II-15
1$100
   4SC-201 (4SC).....II-16
CTCE-9908 (Chemokine Therapeutics).....II-16
1$100
   ARQ 197 (ArQule, Inc.).....II-171$100
   Liver – A Vital Organ.....II-18
Functions of the Liver.....II-18
Overview of Liver Cancer.....II-18
1$100
   Benign Liver Tumors.....II-19
Types of Benign Liver Tumors.....II-19
Hemangiomas.....II-19
Hepatic Adenomas.....II-19
Focal Nodular Hyperplasia.....II-19
Malignant Liver Tumors.....II-19
1$100
   Types of Liver Cancer.....II-20
Hepatocellular Carcinoma (HCC).....II-20
Cholangiocarcinomas.....II-20
Hepatoblastoma.....II-20
Hemangiosarcomas and Angiosarcomas.....II-20
Hepatoblastoma.....II-20
1$100
   Secondary Liver Cancer or Metastatic Cancer.....II-21
Risk Factors.....II-21
Symptoms of Liver Cancer.....II-21
1$100
   Tests for Detection of Liver Cancer.....II-221$100
   Diagnosis of Liver Cancer.....II-23
Blood Tests.....II-23
Imaging Studies.....II-23
1$100
   Ultrasound.....II-24
Computed Tomography.....II-24
Magnetic Resource Imaging.....II-24
Angiography.....II-24
FDG-PET.....II-24
1$100
   Biopsy.....II-25
Prognosis of Liver Cancer.....II-25
1$100
   Treatment Of Liver Cancer.....II-26
Targeted Therapy.....II-26
Working of Targeted Cancer Therapies.....II-26
1$100
   Development of Targeted Therapies.....II-27
Effect of Targeted Therapies on the Treatment of Cancer.....II-27
Chemotherapy.....II-27
1$100
   Surgery.....II-28
Side Effects and Risks Associated with Surgery.....II-28
Cryosurgery.....II-28
1$100
   Benefits of Cryosurgery.....II-29
Limitations of Cryosurgery.....II-29
Liver Transplant.....II-29
Side effects and Risks Associated with Liver Transplantation.....II-29
Tumor Embolization and Ablation.....II-29
1$100
   Radiation Therapy.....II-30
Side-effects Associated with Radiation Therapy.....II-30
Radiofrequency Ablation.....II-30
1$100
   Hepatic Artery Chemoembolization.....II-31
A Focus on Hepatocellular Carcinoma.....II-31
Epidemiology.....II-31
Pathogenesis.....II-31
1$100
   Pathology.....II-32
Prognosis and Staging.....II-32
Treatment.....II-32
1$100
   Treatment Follow-up.....II-331$100
   Bayer Secures Japanese Approval for Nexavar®.....II-34
Bayer Obtains Approval for Nexavar in China.....II-34
Bayer Obtains Approval for Marketing Nexavar® in Singapore.....II-34
Bayer Receives Health Canada's Approval for Nexavar.....II-34
Bayer Obtains FDA Approval for Nexavar in Treating Liver Cancer.....II-34
1$100
   Bayer Receives EU Clearance for Marketing Nexavar.....II-351$100
   NICE Refuses to Take Nexavar on National Health Service (NHS).....II-36
Delcath’s Doxorubicin Obtains Orphan-Drug Designation from FDA.....II-36
CACMS Obtains Clearance for Traditional Chinese Medicine for Liver Cancer.....II-36
Curetech Obtains FDA Approval to Commence Trial on CT-011.....II-36
Bayer Mulls Over Legal Recourse to Avert Nexavar’ Generic in India.....II-36
1$100
   Jennerex Generates Funds for Developing JX-594.....II-37
Celsion to Extend ThermoDox Phase III Trial to Japan.....II-37
Bayer Commences Phase III trials on Nexavar and Tarceva Combination Therapy.....II-37
1$100
   Tiandiren Pharma Begins Construction of Biotech Park.....II-38
Can-Fite to Commence Phase I/II Trial of CF102.....II-38
Celsion’s ThermoDox Obtains Orphan Drug Designation from FDA.....II-38
1$100
   Alnylam Obtains FDA Clearance to Commence Phase I Trial on ALN-VSP.....II-39
ArQule Enrolls Patients for Phase II Study with ARQ 197 in Hepatocellular
  Carcinoma.....II-39
PharmaSynth Licenses Muparfostat to Global TransBiotech.....II-39
1$100
   Bayer-Onyx Commences Clinical Trials on Nexavar as Adjuvant Therapy.....II-40
Protherics Begins Phase II Clinical Trial on Prolarix.....II-40
Chemokine Obtains Hong Kong DoH Clearance on CTCE-9908.....II-40
AstraZeneca Forges New Alliance for Anti-Cancer Compounds.....II-40
1$100
   BioAlliance Annuls Trials on Transdrug® for Liver Cancer Treatment.....II-41
Chemokine Obtains Health Canada Approval to Start CTCE-9908 Phase II Trial.....II-41
Progen Pharmaceuticals Spins-Off its Manufacturing Business.....II-41
1$100
   Metabasis Obtains EMEA Orphan Drug Designation for Liver Cancer Drug.....II-42
Metabasis Obtains FDA Orphan Drug Designation for Liver Cancer Drug.....II-42
1$100
   4SC AG (Germany).....II-43
Actavis Group, Inc. (USA).....II-43
Alnylam Pharmaceuticals, Inc. (USA).....II-43
1$100
   ArQule, Inc. (USA).....II-441$100
   Bayer Schering Pharma AG (Germany).....II-45
Bristol-Myers Squibb Company (US).....II-45
1$100
   Celsion Corp. (USA).....II-46
Eli Lilly & Company (US).....II-46
1$100
   ImClone Systems Inc......II-47
F. Hoffmann–La Roche Ltd. (Switzerland).....II-47
1$100
   Jennerex Biotherapeutics, Inc. (USA).....II-48
Onyx Pharmaceuticals, Inc. (USA).....II-48
1$100
   Pfizer Inc. (USA).....II-49
Progen Pharmaceuticals Ltd. (Australia).....II-49
1$100
   Teva Pharmaceutical Industries Ltd. (Israel).....II-501$100
   Table 4: World Recent Past, Current & Future Analysis for Liver Cancer Drugs Market Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-511$350
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com